Results
965
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
965 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
GRF | €9.07 | -1.2% | -29.1% | €5.6b | €17.34 | PE32.6x | E27.7% | n/a | Pharmaceuticals & Biotech | ||
STKL | US$5.30 | 1.3% | -14.1% | US$632.8m | US$9.83 | PB3.8x | E130.3% | n/a | Food, Beverage & Tobacco | ||
ATLC | US$35.77 | -0.6% | -5.9% | US$529.1m | US$39.67 | PE6.8x | E25.0% | n/a | Diversified Financials | ||
4480 | JP¥4,060.00 | -1.1% | -17.4% | JP¥131.7b | JP¥5,800.00 | PE49.3x | E28.7% | n/a | Healthcare | ||
SLAB | US$120.13 | 3.0% | -15.5% | US$3.9b | US$139.75 | PS7.2x | E106.2% | n/a | Semiconductors | ||
ZYXI | US$9.00 | -11.7% | 5.9% | US$285.7m | US$17.50 | PE47.3x | E41.3% | n/a | Healthcare | ||
LBL | AU$0.68 | -4.2% | -18.1% | AU$79.4m | AU$1.25 | PE17.9x | E33.3% | 2.4% | Capital Goods | ||
PSAN | €21.50 | 1.4% | -14.9% | €333.0m | €29.85 | PS1.2x | E61.2% | 1.9% | Software | ||
6958 | JP¥543.00 | 1.7% | 9.0% | JP¥38.7b | JP¥950.00 | PE10x | E22.5% | 3.5% | Tech | ||
FEX | AU$0.43 | 10.3% | 43.3% | AU$298.7m | n/a | PE7.4x | E24.6% | 4.7% | Materials | ||
GRNG | SEK 130.70 | -3.5% | 25.4% | SEK 13.9b | SEK 155.00 | PE14x | E20.9% | 2.3% | Materials | ||
605016 | CN¥16.62 | -3.9% | -6.1% | CN¥5.5b | CN¥25.38 | PE24.9x | E29.9% | 1.1% | Food, Beverage & Tobacco | ||
A214420 | ₩9,540.00 | -2.5% | 112.2% | ₩228.0b | n/a | PE93.6x | E50.1% | 0% | Household | ||
300218 | CN¥15.19 | 7.3% | 57.7% | CN¥3.2b | CN¥20.00 | PE25.8x | E30.5% | 0.9% | Consumer Durables | ||
TYRES | €8.43 | 7.0% | -0.4% | €1.2b | €7.94 | PE197x | E60.0% | 6.5% | Automobiles | ||
300590 | CN¥12.00 | 11.3% | 7.8% | CN¥5.5b | CN¥14.18 | PE29.8x | E27.5% | 1.3% | Tech | ||
LPRO | US$6.30 | 2.6% | -40.3% | US$750.7m | US$7.75 | PE51.4x | E42.6% | n/a | Diversified Financials | ||
A326030 | ₩85,700.00 | 1.7% | -9.3% | ₩6.7t | ₩107,437.50 | PS16.4x | E84.9% | n/a | Pharmaceuticals & Biotech | ||
ARGX | €466.60 | 8.8% | 2.5% | €27.9b | €486.74 | PS18.2x | E59.4% | n/a | Pharmaceuticals & Biotech | ||
PAAS | CA$31.74 | 7.2% | 54.1% | CA$11.5b | CA$35.55 | PS3.3x | E76.4% | 1.7% | Materials | ||
PRGS | US$58.40 | 1.7% | -3.8% | US$2.5b | US$63.00 | PE34.1x | E21.2% | 1.2% | Software | ||
GLBE | US$34.32 | -0.6% | -17.1% | US$5.7b | US$43.58 | PS9.6x | E91.7% | n/a | Retail | ||
DXN | RM 0.66 | 3.1% | -9.7% | RM 3.3b | n/a | PE10.2x | E13.0% | 6.1% | Household | ||
2373 | HK$16.70 | -0.8% | -14.3% | HK$3.9b | HK$17.55 | PE16.9x | E20.1% | 2.8% | Consumer Services |